NCT02478892 Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
| NCT ID | NCT02478892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2015-05 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2015-05 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.
Eligibility Criteria
Inclusion Criteria * Age \>= 18 * Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation * If no history of PDAC in a first or second degree relative, age \>= 50 * If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer Exclusion Criteria • Pregnancy
Contact & Investigator
Bryson Katona, MD
✉ Bryson.Katona@pennmedicine.upenn.eduFrequently Asked Questions
Who can join the NCT02478892 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02478892 currently recruiting?
Yes, NCT02478892 is actively recruiting participants. Contact the research team at Bryson.Katona@pennmedicine.upenn.edu for enrollment information.
Where is the NCT02478892 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT02478892 clinical trial?
NCT02478892 is sponsored by Abramson Cancer Center at Penn Medicine. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.